Literature DB >> 29209651

PML degradation fosters an immunosuppressive and pro-metastatic tumor microenvironment.

Ya-Ting Wang1,2, Ruey-Hwa Chen1,2.   

Abstract

The tumor suppressive functions of promyelocytic leukemia (PML) have been attributed mainly to its inhibition of various malignant properties of tumor cells. Our recent work identifies a PML ubiquitination and degradation pathway, which regulates both cell and non-cell components of the tumor microenvironment, thereby potentiating immune evasion and metastasis.

Entities:  

Keywords:  CD73; PML; WDR4; metastasis; tumor immunity; ubiquitination

Year:  2017        PMID： 29209651      PMCID： PMC5706947          DOI： 10.1080/23723556.2017.1364212

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Loss of the tumor suppressor PML in human cancers of multiple histologic origins.

Authors:  Carmela Gurrieri; Paola Capodieci; Rosa Bernardi; Pier Paolo Scaglioni; Khedoudja Nafa; Laura J Rush; David A Verbel; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

2.  PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.

Authors:  Rosa Bernardi; Ilhem Guernah; David Jin; Silvia Grisendi; Andrea Alimonti; Julie Teruya-Feldstein; Carlos Cordon-Cardo; M Celeste Simon; Shahin Rafii; Pier Paolo Pandolfi
Journal:  Nature       Date:  2006-08-17       Impact factor: 49.962

3.  Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.

Authors:  Ya-Ting Wang; Jocelyn Chen; Chou-Wei Chang; Jayu Jen; Tzu-Yu Huang; Chun-Ming Chen; Roger Shen; Suh-Yuen Liang; I-Cheng Cheng; Shuenn-Chen Yang; Wu-Wei Lai; Kuang-Hung Cheng; Tao-Shih Hsieh; Ming-Zong Lai; Hung-Chi Cheng; Yi-Ching Wang; Ruey-Hwa Chen
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

Review 4.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

Review 5.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

Review 6.  CD73: a potent suppressor of antitumor immune responses.

Authors:  Paul A Beavis; John Stagg; Phillip K Darcy; Mark J Smyth
Journal:  Trends Immunol       Date:  2012-04-07       Impact factor: 16.687

7.  Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.

Authors:  Paul A Beavis; Nicole Milenkovski; Melissa A Henderson; Liza B John; Bertrand Allard; Sherene Loi; Michael H Kershaw; John Stagg; Phillip K Darcy
Journal:  Cancer Immunol Res       Date:  2015-02-11       Impact factor: 11.151

Review 8.  New insights into the role of PML in tumour suppression.

Authors:  P Salomoni; B J Ferguson; A H Wyllie; T Rich
Journal:  Cell Res       Date:  2008-06       Impact factor: 25.617

Review 9.  Serum amyloid A: an acute-phase protein involved in tumour pathogenesis.

Authors:  E Malle; S Sodin-Semrl; A Kovacevic
Journal:  Cell Mol Life Sci       Date:  2009-01       Impact factor: 9.261

Review 10.  The role of PML ubiquitination in human malignancies.

Authors:  Ruey-Hwa Chen; Yu-Ru Lee; Wei-Chien Yuan
Journal:  J Biomed Sci       Date:  2012-08-30       Impact factor: 8.410
  10 in total
  1 in total

Review 1.  Targeting the Ubiquitin Signaling Cascade in Tumor Microenvironment for Cancer Therapy.

Authors:  Qi Liu; Bayonle Aminu; Olivia Roscow; Wei Zhang
Journal:  Int J Mol Sci       Date:  2021-01-14       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.